UMRS Inserm U "Imagerie et Cerveau" - Université François Rabelais de Tours, France.
Curr Pharm Des. 2012;18(23):3406-15.
Treatment of recurrent or unresectable cutaneous and subcutaneaous tumors continues to be a major therapeutic challenge. Electrochemotherapy (ECT) is a palliative treatment of cutaneous and subcutaneous tumor nodules for which standard treatments (e.g. radiotherapy, chemotherapy, and surgery) have failed or proved to be insufficient. ECT combines the electropulsation of tumor cells (by local application of electric pulses) and the administration of antineoplastic drugs such as cisplatin or bleomycin (either intravenous or intratumoral). The permeability of the cancer cells to these poorly permeant anti-tumor drugs is transiently increased up to a hundred-fold. ECT is thus an efficient loco-regional therapy for palliative treatment of unresectable recurrent tumor nodules with overall objective response rates of approximatively 80-90% and has satisfactory cosmetic results. The next challenge for ECT is the treatment of deep-seated tumors and metastases. The joint therapy of ECT and electrotransfer of immune-stimulating genes or electro-photodynamic therapy could be a promising strategy for cancer eradication.
复发性或不可切除的皮肤和皮下肿瘤的治疗仍然是一个主要的治疗挑战。电化疗 (ECT) 是一种姑息性治疗皮肤和皮下肿瘤结节的方法，对于标准治疗（如放疗、化疗和手术）失败或证明不足的肿瘤结节有效。ECT 将肿瘤细胞的电脉冲（通过局部施加电脉冲）与顺铂或博来霉素等抗癌药物的给药（静脉内或肿瘤内）相结合。癌细胞对这些渗透性差的抗癌药物的通透性暂时增加了一百倍。因此，ECT 是一种有效的局部区域治疗方法，可姑息治疗不可切除的复发性肿瘤结节，总客观缓解率约为 80-90%，并且具有令人满意的美容效果。ECT 的下一个挑战是治疗深部肿瘤和转移。ECT 联合免疫刺激基因的电转移或电光动力疗法可能是一种有前途的癌症消除策略。
